论文部分内容阅读
依次应用米非司酮(mifepristone)和米索前列醇(misoprostol)的预期多中心流产试验研究的开展旨在为支持降低流产所需的米非司酮推荐剂量至200mg并允许回家服用400μg米索前列醇提供数据。所有的受试对象均停经(已确诊妊娠)不足50天、年龄18岁或18岁以上且无米非司酮应用禁忌症;受试者在注册参加试验的当天,经咨询和医学检查后,每人服用200mg米非司酮,回家后48小时内服用2200μg米索前列醇片剂,并要求其每天记录症状,2周后返回进行评估;对继续妊娠或未完全流产的妇女实施真空吸引术。在最初注册试验的376例患者中,354例受试者符合研究方案的所有条件,研究进行到中期时,
The prospective multicenter abortion pilot study that followed sequential application of mifepristone and misoprostol was initiated in order to support the recommended dose of mifeprist required to reduce miscarriage to 200 mg and to allow 400 μg of home Supramoetin provides data. All subjects were menopausal (diagnosed pregnancy) less than 50 days, aged 18 years or older and no contraindications to mifepristone; the subjects participated in the registration test on the day after consultation and medical examination, Taking 200 mg of mifepristin per person and taking 2200 μg of misoprostol tablets within 48 hours of going home and requiring daily recording of symptoms and return after 2 weeks for evaluation; vacuuming of women who continued or incomplete abortion Surgery. Of the 376 patients initially enrolled in the trial, 354 subjects met all of the criteria for the study protocol. By the middle of the study,